ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
1.720
-0.070 (-3.91%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Company Description
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States.
The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Bruce Culleton |
Contact Details
Address: 2000 Frontis Plaza Blvd., Suite 250 Winston-Salem, North Carolina 27103 United States | |
| Phone | 336 999 7028 |
| Website | prokidney.com |
Stock Details
| Ticker Symbol | PROK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850270 |
| ISIN Number | KYG7S53R1049 |
| Employer ID | 98-1586514 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bruce Culleton M.D. | Chief Executive Officer and Director |
| Dr. Timothy A. Bertram D.V.M., Ph.D. | Founder |
| James Coulston CPA | Chief Financial Officer |
| Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer and Secretary |
| Carla Poulson | Chief People Officer |
| Dr. Joseph M. Stavas M.D., M.P.H. | Senior Vice President of Interventional Procedures and Patient Safety |
| Dr. Darin J. Weber Ph.D. | Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics and Market Access |
| Nikhil L. Pereira-Kamath | Chief Business Officer |
| Richard Williams | Senior Vice President of Information Technology |
| Dr. Aparna Sahoo M.D. | Vice President and Head of Global Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 19, 2024 | 144 | Filing |
| Sep 3, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 9, 2024 | 8-K | Current Report |
| Jun 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 13, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 424B5 | Filing |